PHASQ PhaseBio Pharmaceuticals (PNK) plunges 99.00% on 20 Jan 2026: liquidity risk needs monitoring
PHASQ stock collapsed about -99.00% to roughly $0.000001 on 20 Jan 2026 during US market hours, highlighting severe liquidity strain for PhaseBio Pharmaceuticals, Inc. (PNK). Trading volume was light at 2,500.00 shares versus an average of 22,310.00, and the previous close was $0.0001. The steep move follows continued delisting and Chapter 11 concerns, driving near-zero market capitalization and extreme volatility for this biotechnology name in the United States.
PHASQ stock price action and volume
PHASQ shares traded at $0.000001 with a one-day change of -99.00% during regular market hours on 20 Jan 2026. Volume was 2,500.00, well below the 50-day average of 22,310.00, signaling very thin liquidity and large bid-ask spreads. Low liquidity amplifies price moves and makes execution risk high for orders above small sizes on the PNK exchange in the United States.
Why PhaseBio Pharmaceuticals (PHASQ) plunged
The decline ties to bankruptcy restructuring history and potential delisting reports that reduce investor confidence and reduce trading interest. Market commentary flagged potential delisting status and limited quote data; see reporting from Nasdaq and MarketBeat for context Nasdaq MarketBeat. Regulatory or exchange actions and sparse market makers are primary drivers of the near-total price collapse.
Financials and valuation snapshot
PhaseBio lists EPS of -2.14 and negative valuation ratios, reflecting ongoing losses and minimal revenue. Trailing metrics show a 50-day average price around 0.000 and 200-day average near 0.001, indicating sustained weakness relative to the year high of 0.04. Balance sheet figures show cash per share of 1.42 (TTM metric) but negative book value per share of -3.16, underscoring distressed equity fundamentals in the Healthcare Biotechnology sector.
Meyka AI rates PHASQ with a score out of 100
Meyka AI rates PHASQ with a score out of 100: 58.92 (Grade: C+, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects weak trading liquidity, negative earnings, and restructuring risk, not a recommendation to buy or sell.
Meyka AI forecast and price targets
Meyka AI’s forecast model projects a near-term price centered at $0.000 versus the current quoted $0.000001, implying a downside near -100.00% on a rounded basis. Analysts lack consensus price targets, so we present scenario targets: bear $0.00, base $0.00, and a remote bull target near the year high of $0.04. Forecasts are model-based projections and not guarantees; sparse liquidity and delisting risk make any target highly speculative.
Risks, technicals and sector context
Key risks: potential delisting, Chapter 11 aftermath, minimal liquidity, and continued R&D funding needs for the biotech pipeline. Technical indicators are unreliable given near-zero pricing, so traders should treat stop orders cautiously. Sector performance in Healthcare and Biotechnology remains mixed, and PHASQ’s microcap status isolates it from broader sector rallies.
Final Thoughts
PHASQ stock’s sharp -99.00% drop on 20 Jan 2026 reflects severe liquidity failure and ongoing corporate distress for PhaseBio Pharmaceuticals, Inc. (PNK) in the United States. With quoted price at roughly $0.000001, daily volume at 2,500.00, negative EPS -2.14, and thin market-making, the equity shows very high execution and delisting risk. Meyka AI’s proprietary grade sits at 58.92 (C+, HOLD) and our forecast model projects a rounded near-term price of $0.000, which implies a roughly -100.00% downside versus the quoted level; forecasts are model-based and not guarantees. For investors, the primary conclusion is risk-control: limit exposure, avoid large positions, and monitor official exchange notices and filings. For more live details consult the company site and exchange filings, and check our Meyka AI PHASQ page for real-time updates and alternative data signals.
FAQs
Why did PHASQ stock fall sharply on 20 Jan 2026?
PHASQ’s plunge ties to bankruptcy restructuring history, possible delisting reports, and extremely low liquidity. Sparse market makers and limited trading volume magnified the move.
What is Meyka AI’s view on PHASQ stock?
Meyka AI assigns PHASQ a 58.92 score (Grade C+, Suggestion HOLD). The grade reflects weak liquidity, negative earnings, and sector headwinds in biotechnology.
Are there realistic price targets for PHASQ stock?
Given trading constraints and no analyst consensus, scenario targets are: bear $0.00, base $0.00, remote bull $0.04. These are highly speculative and model-based.
How should investors manage PHASQ trading risk?
Limit position size, use limit orders, avoid market orders, and watch official Nasdaq or exchange notices. Track filings and liquidity before acting on PHASQ stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
